BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial
Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma ...